MedVellum
MedVellum
Back to Library
Dermatology
Emergency Medicine
General Practice
EMERGENCY

Cellulitis & Erysipelas

High EvidenceUpdated: 2025-12-23

On This Page

Red Flags

  • Pain out of proportion to signs (necrotising fasciitis)
  • Rapidly spreading erythema despite antibiotics
  • Crepitus on palpation
  • Haemodynamic instability (sepsis)
  • Blue/purple skin discoloration or bullae
  • Orbital involvement (eye movement restriction, proptosis)
  • Facial cellulitis (risk of cavernous sinus thrombosis)
Overview

Cellulitis & Erysipelas

1. Clinical Overview

Summary

Cellulitis and erysipelas are common acute bacterial skin and soft tissue infections (SSTIs). Cellulitis involves the deeper dermis and subcutaneous fat with ill-defined spreading margins, while erysipelas is more superficial, involving the upper dermis and lymphatics with characteristically well-demarcated, raised edges. Both typically present with erythema, warmth, swelling, and tenderness, often with systemic symptoms. Group A Streptococcus (Streptococcus pyogenes) is the most common causative organism, followed by Staphylococcus aureus. Most cases respond to oral antibiotics (flucloxacillin), but severe infections require IV therapy. Critically, cellulitis must be differentiated from necrotising fasciitis, a surgical emergency.

Key Facts

  • Definition: Acute spreading bacterial infection of skin and subcutaneous tissue
  • Incidence: 200 per 100,000 person-years; 2-4% of emergency department presentations
  • Most common organisms: Streptococcus pyogenes (Group A Strep) and Staphylococcus aureus
  • Most common site: Lower limb (70-80%)
  • Key differentiator: Erysipelas has raised, sharply demarcated edges; cellulitis has ill-defined margins
  • First-line treatment: Flucloxacillin 500mg-1g QDS orally (or IV if severe)
  • Critical mimic: Necrotising fasciitis (pain out of proportion, rapid spread)

Clinical Pearls

Eron Classification: Use this to guide oral vs IV antibiotics and disposition. Class I-II can be managed as outpatients; Class III-IV need admission.

Draw the Line: Mark the leading edge of erythema with permanent marker and timestamp it. This is the most reliable way to track progression or response to treatment.

Treat the Portal: Most lower limb cellulitis occurs due to tinea pedis (athlete's foot) or leg ulcers providing entry for bacteria. Always check between the toes and treat any interdigital maceration.

Why This Matters Clinically

Cellulitis is the 4th most common reason for emergency hospital admission for infection. While most cases are straightforward, failure to recognise necrotising fasciitis leads to delayed surgery and high mortality (30-40%). Recurrent cellulitis occurs in 20-30% of patients, often due to untreated risk factors like lymphoedema or tinea pedis.


2. Epidemiology

Incidence & Prevalence

  • Incidence: 200 per 100,000 person-years
  • Hospital admissions: 6.5 per 1000 admissions in UK
  • Recurrence rate: 20-30% within 3 years
  • Trend: Increasing with ageing population and obesity

Demographics

FactorDetails
AgePeak incidence in adults over 65
SexEqual or slight male predominance
SiteLower limb 70-80%; face, arm, other 20-30%
SeasonalSlight summer increase

Risk Factors

Non-Modifiable:

  • Previous cellulitis (strongest risk factor — OR 10-20)
  • Lymphoedema / venous insufficiency
  • Surgical disruption of lymphatics (e.g., mastectomy, saphenous vein harvest)

Modifiable:

Risk FactorRelative Risk
Tinea pedis (athlete's foot)2-3x
Obesity2-4x
Leg ulcers2-3x
Diabetes mellitus1.5-2x
Peripheral vascular disease2x
Immunosuppression2-3x
IV drug use3-5x (especially MRSA)

3. Pathophysiology

Mechanism

Step 1: Breach in Skin Barrier

  • Trauma (even minor), insect bites, surgeryincisions, or interdigital tinea pedis
  • Fissures between toes are most common portal for lower limb cellulitis
  • Leg ulcers, eczema, and dermatitis also provide entry points

Step 2: Bacterial Invasion

  • Streptococcus pyogenes (GAS) or Staphylococcus aureus enter dermis
  • Streptococci produce enzymes (streptokinase, hyaluronidase) aiding spread
  • Staphylococci tend to cause more localised infection with abscess formation

Step 3: Inflammatory Response

  • Host immune response causes erythema, oedema, warmth
  • Cytokine release leads to systemic symptoms (fever, malaise)
  • Lymphangitis may occur (red streaking toward lymph nodes)

Step 4: Spread or Resolution

  • If untreated, infection spreads horizontally through skin layers
  • Risk of bacteraemia, abscess formation, or rarely necrotising fasciitis
  • With treatment, resolution typically within 5-10 days

Classification

Cellulitis vs Erysipelas:

FeatureCellulitisErysipelas
DepthDeeper dermis + subcutaneous fatUpper dermis + superficial lymphatics
EdgeIll-defined, diffuseWell-demarcated, raised (peau d'orange)
SurfaceFlatRaised, indurated
OrganismS. aureus and/or GASPredominantly GAS
Systemic symptomsVariableOften prominent early
SiteMost common: lower legFace and lower limbs

Eron Classification (Severity):

ClassFeaturesManagement
INo systemic toxicity, no comorbiditiesOutpatient oral antibiotics
IISystemic toxicity OR unstable comorbidityOutpatient or brief observation
IIISignificant systemic upset, partial treatment failureInpatient IV antibiotics
IVSepsis, necrotising fasciitisICU, surgical debridement

Anatomical Considerations

  • Lower limb predilection due to dependent oedema, venous stasis, and proximity to tinea pedis
  • Facial cellulitis: Risk of spread to periorbital or orbital structures, cavernous sinus
  • Perineal cellulitis: Consider Fournier's gangrene (necrotising fasciitis)

4. Clinical Presentation

Symptoms

Typical Presentation:

Associated Symptoms:

Atypical Presentations:

Signs

Local Signs:

Systemic Signs:

Portal of Entry:

Red Flags

[!CAUTION] Red Flags — URGENT surgical review required if:

  • Pain out of proportion to clinical signs (suggests necrotising fasciitis)
  • Rapid progression of erythema despite antibiotics (greater than 1cm/hour)
  • Crepitus on palpation (gas in tissues — NF or gas gangrene)
  • Bullae with purple/dusky discoloration
  • Skin necrosis
  • Haemodynamic instability (sepsis)
  • Immunocompromise with severe presentation

Acute onset erythema (redness) of affected area (100%)
Common presentation.
Pain or tenderness (90%)
Common presentation.
Swelling (85%)
Common presentation.
Warmth (85%)
Common presentation.
Fever, malaise, rigors (50-70% — more common in erysipelas)
Common presentation.
5. Clinical Examination

Structured Approach

General:

  • Observations: Temperature, HR, BP, RR, SpO2 (sepsis screening)
  • General appearance: Ill/toxic vs well
  • NEWS score if in hospital setting

Local Skin Examination:

  • Inspect: Define extent of erythema, demarcation, surface changes
  • Palpate: Warmth, tenderness, oedema (pitting?), crepitus
  • Mark the edge: Use permanent marker with date/time
  • Measure: Size of area affected

Portal of Entry Search:

  • Interdigital spaces: Look for tinea pedis (maceration, scaling)
  • Leg ulcers: Venous or arterial
  • Wounds, insect bites, abrasions
  • Postoperative incisions (if recent surgery)

Regional Examination:

  • Lymph nodes: Inguinal (lower limb), axillary (upper limb), cervical (facial)
  • Lymphangitis: Red streaking toward lymph nodes

Special Tests

TestTechniquePositive FindingClinical Significance
NEWS/qSOFAVital signs scoringScore ≥2Sepsis — escalate care
Finger testPass finger along skin under local anaesthesiaLack of bleeding, dishwater pusSuggests necrotising fasciitis
ElevationRaise affected limbRapid improvement suggests venous aetiology, not infectionHelps differentiate stasis
Drawing the lineMark erythema edge, review in 24-48hExpansion beyond lineTreatment failure

6. Investigations

First-Line (Bedside)

  • Observations — Sepsis screen (NEWS, qSOFA)
  • Capillary blood glucose — Exclude/assess diabetes
  • Examination of interdigital spaces — Tinea pedis

Laboratory Tests

TestExpected FindingPurpose
FBCLeukocytosis (WCC greater than 10 × 10⁹/L)Assess inflammatory response
CRPElevatedInfection marker; useful for monitoring
U&EsUsually normal; may show AKI in sepsisBaseline, hydration status
Blood culturesPositive in 2-5% (low yield)Consider if febrile, severe, or immunocompromised
Glucose / HbA1cMay reveal undiagnosed diabetesModifiable risk factor
LactateElevated in sepsisSepsis severity marker

Imaging

ModalityFindingsIndication
UltrasoundFluid collection / abscessIf fluctuance suspected; guide drainage
Plain X-raySoft tissue gas (clostridial infection, NF)If crepitus present
CT with contrastFat stranding, gas tracking, fascial thickeningIf necrotising fasciitis suspected
MRIFascial enhancementMost sensitive for NF; may delay surgery — clinical diagnosis preferred

Diagnostic Criteria

Clinical Diagnosis (No specific criteria required):

  • Typical clinical features (erythema, warmth, swelling, tenderness) ± systemic symptoms
  • Blood tests are supportive but not diagnostic
  • Cultures often negative (organisms in tissue, not blood)

7. Management

Management Algorithm

Conservative Management

  • Mark erythema edge — With permanent marker and time; review in 24-48h
  • Limb elevation — Reduces oedema, aids resolution
  • Treat portal of entry — Antifungal for tinea pedis (terbinafine cream, nystatin)
  • Analgesia — Paracetamol ± NSAIDs
  • Compression stockings — After acute episode resolves if venous insufficiency

Medical Management

Oral Antibiotics (Eron Class I-II):

DrugDoseDurationNotes
Flucloxacillin500mg-1g QDS5-7 daysFirst-line
Co-amoxiclav625mg TDS5-7 daysAlternative
Clarithromycin500mg BD5-7 daysPenicillin allergy
Doxycycline200mg stat then 100mg BD7 daysPenicillin allergy

IV Antibiotics (Eron Class III-IV):

DrugDoseIndication
Flucloxacillin IV1-2g QDSSevere cellulitis
Benzylpenicillin IV1.2g QDSAdd if streptococcal suspected
Clindamycin IV600mg-1.2g TDSPenicillin allergy; or add in NF (toxin suppression)
Vancomycin IVPer levelsMRSA suspected (IVDU, previous MRSA)

IV to Oral Switch:

  • Improvement in local signs
  • Systemically well, afebrile for 24-48 hours
  • Able to tolerate oral medication

Surgical Management

Indications:

  • Abscess requiring drainage (incision and drainage)
  • Necrotising fasciitis (emergency surgical debridement)
  • Non-responding cellulitis with underlying foreign body

Disposition

  • Discharge with oral antibiotics: Eron Class I-II, well, reliable follow-up
  • Admit for IV antibiotics: Eron Class III-IV, sepsis features, failure of oral therapy
  • Follow-up: 48-72 hours review (GP or clinic) to assess response to treatment

8. Complications

Immediate (Hours)

ComplicationIncidencePresentationManagement
Sepsis5-10% of admissionsFever, tachycardia, hypotensionIV antibiotics, fluids, sepsis bundle
Progression to necrotising fasciitisRare (less than 1%)Severe pain, rapid spread, crepitusEmergency surgical debridement

Early (Days-Weeks)

  • Abscess formation: Fluctuance develops; requires drainage
  • Treatment failure: Non-response after 48-72h — consider MRSA, abscess, wrong diagnosis
  • Bacteraemia: Positive blood cultures (2-5%); may need prolonged IV therapy
  • Deep vein thrombosis: Leg swelling may mask or predispose; consider if persistent swelling

Late (Weeks-Months)

  • Recurrence: 20-30% within 3 years; often at same site
  • Post-cellulitis syndrome: Persistent oedema and hyperpigmentation; not infection
  • Secondary lymphoedema: Damage to lymphatics leads to chronic swelling
  • Chronic ulceration: Especially in patients with venous insufficiency

9. Prognosis & Outcomes

Natural History

  • Without treatment: Progressive spread, systemic sepsis, potential for necrotising fasciitis
  • With treatment: Resolution within 5-10 days; most respond to oral antibiotics

Outcomes with Treatment

VariableOutcome
Response to oral antibiotics70-80%
Need for IV step-up20-30%
Hospital admission rate15-20% of all presentations
Mortalityless than 1% (higher in NF: 20-40%)
Recurrence20-30% (higher if lymphoedema)

Prognostic Factors

Good Prognosis:

  • Young, fit patient
  • First episode
  • No comorbidities
  • Portal of entry addressed (tinea treated)
  • Early presentation

Poor Prognosis:

  • Diabetes mellitus
  • Immunosuppression
  • Lymphoedema
  • Prior cellulitis at same site
  • Delay in treatment
  • Advancing age

10. Evidence & Guidelines

Key Guidelines

  1. NICE NG141 (2019) — Cellulitis and erysipelas: antimicrobial prescribing. Recommends flucloxacillin first-line; 5-7 day course. NICE NG141
  2. CREST Guidelines (2005) — Guidelines on the management of cellulitis in adults. Early UK regional guidance, widely influential. CREST
  3. PHE/NICE Antimicrobial Prescribing (2019) — Antibiotic choice based on local resistance patterns. PHE

Landmark Trials

PATCH I Trial (Thomas et al., 2011) — Prophylactic antibiotics for recurrent cellulitis

  • 274 patients with recurrent cellulitis randomised to penicillin V or placebo
  • Key finding: Penicillin reduced recurrence by 45% while on treatment
  • Clinical Impact: Supports prophylactic antibiotics in recurrent cases

PATCH II Trial (2017) — Follow-up of PATCH I

  • Extended analysis showed effect wanes after stopping prophylaxis
  • Clinical Impact: Raises question of appropriate duration of prophylaxis

Kilburn et al. (2010) — Eron classification validation

  • Demonstrated that Eron classification predicts need for hospitalisation and IV therapy
  • Clinical Impact: Widely adopted for severity stratification

Evidence Strength

InterventionLevelKey Evidence
Flucloxacillin first-line1aNICE systematic review
5-7 day antibiotic course1bRCTs
Limb elevation2bObservational evidence
Prophylactic penicillin for recurrence1bPATCH Trial

11. Patient/Layperson Explanation

What is Cellulitis?

Cellulitis is a skin infection caused by bacteria that have got under the skin, usually through a small cut, insect bite, or cracked skin (like athlete's foot between your toes). The skin becomes red, swollen, warm, and painful. It can spread if not treated and sometimes makes you feel generally unwell with a fever.

Is it serious?

For most people, cellulitis is uncomfortable but treatable with antibiotics. However, if it spreads quickly, causes severe pain, or you become very unwell, it can be a sign of a more serious infection that needs urgent hospital treatment.

How is it treated?

  1. Antibiotics: Most people take tablets (usually flucloxacillin) for 5-7 days. If the infection is more severe, you may need antibiotics through a drip in hospital.
  2. Resting the area: Keeping the affected limb raised (e.g., leg on a stool) helps reduce swelling.
  3. Treating the cause: If you have athlete's foot or a skin break that let the bacteria in, this should also be treated to prevent recurrence.
  4. Marking the edge: The doctor may draw around the red area with a pen to track whether it's getting better or worse.

What to expect

  • The area may look worse initially before improving (redness may deepen as inflammation resolves)
  • Improvement is usually seen within 2-3 days of starting antibiotics
  • Full resolution takes 5-10 days
  • There may be some residual discolouration or swelling for weeks

When to seek help

Go back to your doctor or seek urgent medical attention if:

  • The redness is spreading rapidly (faster than you can mark it)
  • The pain is getting much worse despite painkillers
  • You develop new blisters, blackish discolouration, or the skin looks dusky
  • You feel increasingly unwell (fever, shivering, confusion)
  • The antibiotics aren't helping after 2-3 days

12. References

Primary Guidelines

  1. National Institute for Health and Care Excellence. Cellulitis and erysipelas: antimicrobial prescribing (NG141). 2019. NICE NG141
  2. Public Health England. Management of infection guidance for primary care. 2019.

Key Trials

  1. Thomas KS, et al. Penicillin to prevent recurrent leg cellulitis. N Engl J Med. 2013;368(18):1695-1703. PMID: 23635049
  2. Thomas KS, et al. Penicillin prophylaxis for recurrent cellulitis: the PATCH trial follow-up. Br J Dermatol. 2017;176(5):1225-1232. PMID: 27943246
  3. Eron LJ, et al. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother. 2003;52 Suppl 1:i3-17. PMID: 14662806
  4. Raff AB, Kroshinsky D. Cellulitis: A Review. JAMA. 2016;316(3):325-337. PMID: 27434444

Further Resources

  • NHS Cellulitis: nhs.uk/conditions/cellulitis
  • DermNet NZ Cellulitis: dermnetnz.org/topics/cellulitis
  • British Association of Dermatologists: bad.org.uk


Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always seek urgent medical advice if necrotising fasciitis is suspected.

Last updated: 2025-12-23

At a Glance

EvidenceHigh
Last Updated2025-12-23
Emergency Protocol

Red Flags

  • Pain out of proportion to signs (necrotising fasciitis)
  • Rapidly spreading erythema despite antibiotics
  • Crepitus on palpation
  • Haemodynamic instability (sepsis)
  • Blue/purple skin discoloration or bullae
  • Orbital involvement (eye movement restriction, proptosis)

Clinical Pearls

  • **Eron Classification**: Use this to guide oral vs IV antibiotics and disposition. Class I-II can be managed as outpatients; Class III-IV need admission.
  • **Draw the Line**: Mark the leading edge of erythema with permanent marker and timestamp it. This is the most reliable way to track progression or response to treatment.
  • **Red Flags — URGENT surgical review required if:**
  • - Pain out of proportion to clinical signs (suggests necrotising fasciitis)
  • - Rapid progression of erythema despite antibiotics (greater than 1cm/hour)

Guidelines

  • NICE Guidelines
  • BTS Guidelines
  • RCUK Guidelines